Colchicine for Heart Disease: How a Cheap Gout Drug May Prevent Heart Attacks and Strokes

How Does Colchicine Reduce Heart Attack and Stroke Risk?

Cardiovascular disease remains the leading cause of death globally, claiming approximately 17.9 million lives each year according to the World Health Organization. While statins and blood pressure medications have transformed prevention, residual inflammatory risk continues to drive cardiovascular events even in well-treated patients. Colchicine, derived from the autumn crocus plant and used for gout treatment for centuries, targets this inflammatory component directly.

The drug works by inhibiting the NLRP3 inflammasome and reducing interleukin-1β signaling — key drivers of vascular inflammation. It also suppresses neutrophil migration and adhesion to endothelial cells, which are early steps in plaque formation and destabilization. Unlike newer anti-inflammatory biologics that can cost tens of thousands of dollars annually, colchicine is available as a generic medication for under a dollar per day, making it one of the most cost-effective cardiovascular interventions under investigation.

What Does the Clinical Trial Evidence Show?

The landmark COLCOT trial, published in the New England Journal of Medicine in 2019, enrolled over 4,700 patients who had recently suffered a heart attack. Those randomized to receive low-dose colchicine (0.5 mg daily) experienced a significant reduction in the composite endpoint of cardiovascular death, cardiac arrest, heart attack, stroke, or urgent need for coronary revascularization compared to placebo. The LoDoCo2 trial, also published in the New England Journal of Medicine in 2020, confirmed these findings in patients with chronic coronary artery disease, showing a significant reduction in cardiovascular events.

Based on this body of evidence, the U.S. FDA approved a branded formulation of colchicine (Lodoco, 0.5 mg) in June 2023 specifically for reducing the risk of cardiovascular events in adult patients with established atherosclerotic disease or multiple cardiovascular risk factors. The American Heart Association and European Society of Cardiology have also begun incorporating low-dose colchicine into their treatment guidelines. Ongoing research continues to explore whether colchicine may benefit broader populations, including those with heart failure and peripheral artery disease.

What Are the Side Effects and Risks of Long-Term Colchicine Use?

While colchicine has a well-established safety profile from decades of use in gout and familial Mediterranean fever, long-term cardiovascular use does carry some considerations. Gastrointestinal side effects — particularly diarrhea, nausea, and abdominal discomfort — are the most frequently reported adverse events, though these tend to be mild at the 0.5 mg daily dose used in cardiovascular trials. In the COLCOT and LoDoCo2 trials, rates of serious adverse events were similar between colchicine and placebo groups.

Clinicians must be cautious about drug interactions, particularly with strong CYP3A4 inhibitors and P-glycoprotein inhibitors, which can increase colchicine levels and raise the risk of toxicity. Patients with severe kidney or liver disease require dose adjustments or may need to avoid the drug entirely. A small signal for increased infection risk, particularly pneumonia, was observed in some trials and warrants monitoring. Despite these considerations, the overall benefit-risk profile appears favorable for patients with atherosclerotic cardiovascular disease, particularly given the drug's low cost and accessibility.